Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2010

View Archived Issues

Indian scientists claim new inhibitors of TNF-alpha production

Cornerstone Pharma adds new site for phase I/II CPI-613 trials in cancer

Southern Research Institute discloses novel antiviral agents

MannKind discloses new agents for pulmonary drug delivery

Mallinckrodt discovers new diagnostics for renal disorders

Novavax's influenza VLP vaccine triggers cytotoxic T-cell proliferation and IFN-gamma secretion

Clinical data presented on abciximab vs. eptifibatide in PCI

BPR-0912 exhibits antiobesity effects in vivo

Lundbeck identifies highly selective M1 receptor agonist

Lpath provides update on four drug development programs

Galapagos acquires full rights to GLPG-0634 for arthritis

FDA grants fast track status to ACE-031 in Duchenne's muscular dystrophy

Agennix presents update on talactoferrin in cancer and severe sepsis

GlaxoSmithKline presents new antimycobacterial agents

Elder Pharmaceuticals discovers new glucose-lowering agents

Cell Therapeutics reports on second quarter 2010

Italian scientists identify new EGFR inhibitors

Clavis advances phase II gemcitabine elaidate trial in pancreatic cancer

GenVec and Novartis expand collaboration on hearing loss and balance disorders

Impax Laboratories and Perrigo collaborate on topical drug products

FDA to complete review of lorcaserin NDA in October

Glycotope begins phase I trial of GT-MAb 5.2-GEX in cancer

FDA does not grant orphan drug status to Levulan PDT for SCC prevention

FDA approves update of Isentress label with 96-week data of trials in HIV-1 infection

Sunesis partners for phase III VALOR trial of vosaroxin in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...